
Here's how you know



FULL TEXT LINKS



Pediatr Transplant. 2021 Dec;25(8):e14102. doi: 10.1111/petr.14102. Epub 2021 Jul 26.

Pediatric KT in children up to 15 kg: A single-center experience

Andrea Mariana Exeni ¹, German Fernando Falke ², Silvina Montal ³, María Paula Rigali ¹, Débora Raquel Cisnero ¹, Leandro Berberian ², Sofia Marchionatti ², Soledad Heredia ², Hernán Eduardo Allegrotti ⁴, Silvio Fabio Torres ⁵, Ricardo Daniel Russo ², José Rozanec ⁶

Affiliations

PMID: 34309990 DOI: 10.1111/petr.14102

Abstract

Background: KT is the preferred treatment for ESRD in pediatrics. However, it may be challenging in those weighing \leq 15 kg with potential complications that impact on morbidity and graft loss.

Methods: This retrospective review reports our experience in KT in children, weighing \leq 15 kg, and the strategies to reduce morbidity and mortality.

Results: All patients were on RRT prior to KT. Patients reached ESRD mainly due to urologic malformations (54.54%). LD was performed in 82% of patients. The recipient's median age was 2.83 years, and median weight 12.280 kg. Male sex was predominant (73%). All patients required transfusions of PRBCs. There was a high requirement for ventilated support in patients post-KT with no relation to weight, amount of resuscitation used intra-operatively or ml/kg of PRBCs. One patient presented with stenosis of the native renal artery. No patients presented DGF, graft thrombosis, or surgical complications. No association was found between cold ischemia and eGFR at 1 year (p = .12). In univariate analysis, eGFR at 1 year is related to AR. eGFR at 3 years is related to the number of UTI. Median follow-up was 1363 days. Patient and graft survival were 100%.

Conclusions: KT in children ≤15 kg can be challenging and requires a meticulous perioperative management and surgical expertise. Patient and graft survival are excellent with low rate of complications.

Keywords: AR; graft survival; pediatric KT; surgical complications.

© 2021 Wiley Periodicals LLC.

PubMed Disclaimer

LinkOut - more resources

Full Text Sources

Ovid Technologies, Inc.

Wiley

Medical

MedlinePlus Health Information

Research Materials

NCI CPTC Antibody Characterization Program

Miscellaneous

NCI CPTAC Assay Portal